Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 single arm, multiple-cohorts basket trial will evaluate sacituzumab govitecan-hziy in patients with relapse/refractory esophageal squamous cell carcinoma, gastric cancer, and cervical cancer

Next Previous
X
Search
Trial Profile

A Phase 2 single arm, multiple-cohorts basket trial will evaluate sacituzumab govitecan-hziy in patients with relapse/refractory esophageal squamous cell carcinoma, gastric cancer, and cervical cancer

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sacituzumab govitecan (Primary)
  • Indications Cervical cancer; Gastric cancer; Oesophageal cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Sponsors Everest Medicines

    • Most Recent Events

    • 30 Aug 2021 According to a Everest Medicines media release, company plans to initiate this trial in second half of 2021.
    • 07 Apr 2021 New trial record
    • 31 Mar 2021 According to a Everest Medicines media release, China National Medical Products Administration (NMPA) approved its Clinical Trial Application (CTA) for a Phase 2 basket trial of Trodelvy (sacituzumab govitecan-hziy) in a variety of cancers with high TROP-2 expression.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top